Payment overview · 2025
General Payments
$555.37
31 reported records · 12 companies
Healthcare provider profile · identity verified
Rachael E Gross, DO
Allopathic & Osteopathic Physicians|Family Medicine · ORANGEBURG, SC · NPI 1467438853
Verified facts
What the public records show
CMS Open Payments records show Rachael E Gross, DO received $555.37 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 15.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $84.69 | 15.2% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $80.67 | 14.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.95 | 14.0% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.90 | 11.7% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.30 | 9.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.85 | 7.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.81 | 7.0% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $36.35 | 6.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.54 | 5.3% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.22 | 3.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.23 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $13.86 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $555.37 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $80.67 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $64.90 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $64.90 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $62.78 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.30 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $49.24 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.95 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.81 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.54 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.02 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 63 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 79 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
63 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
87 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
79 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 645 | 156 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 601 | 158 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 357 | 80 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 304 | 42 |
| Metformin Hcl | Metformin Hcl | 288 | 66 |
| Alprazolam | Alprazolam | 268 | 47 |
| Omeprazole | Omeprazole | 243 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 64 |
| Gabapentin | Gabapentin | 211 | 59 |
| Lisinopril | Lisinopril | 186 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 178 | 44 |
| Famotidine | Famotidine | 170 | 51 |
| Furosemide | Furosemide | 169 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 46 |
| Losartan Potassium | Losartan Potassium | 165 | 47 |
| Simvastatin | Simvastatin | 164 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 163 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 34 |
| Carvedilol | Carvedilol | 147 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 137 | 27 |
| Valsartan | Valsartan | 135 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 130 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 43 |
| Ezetimibe | Ezetimibe | 122 | 29 |
| Potassium Chloride | Potassium Chloride | 118 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 32 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 111 | 34 |
| Eliquis | Apixaban | 108 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 104 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 98 | suppressed |
| Meloxicam | Meloxicam | 95 | 18 |
| Tramadol Hcl | Tramadol Hcl | 93 | 25 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 90 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 15 |
| Prednisone | Prednisone | 88 | 45 |
| Jardiance | Empagliflozin | 87 | 18 |
| Montelukast Sodium | Montelukast Sodium | 87 | 23 |
| Clonazepam | Clonazepam | 85 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 27 |
| Trazodone Hcl | Trazodone Hcl | 85 | 23 |
| Clonidine Hcl | Clonidine Hcl | 84 | 24 |
| Allopurinol | Allopurinol | 79 | 17 |
| Ozempic | Semaglutide | 79 | 14 |
| Sertraline Hcl | Sertraline Hcl | 79 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 14 |
| Colchicine | Colchicine | 78 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 19 |
| Mounjaro | Tirzepatide | 72 | 14 |
| Lorazepam | Lorazepam | 71 | 18 |
| Donepezil Hcl | Donepezil Hcl | 69 | 12 |
| Nifedipine Er | Nifedipine | 66 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 13 |
| Mirtazapine | Mirtazapine | 64 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 13 |
| Farxiga | Dapagliflozin Propanediol | 63 | 18 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 63 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 15 |
| Glimepiride | Glimepiride | 58 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 58 | 18 |
| Chlorthalidone | Chlorthalidone | 57 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 42 |
| Fluconazole | Fluconazole | 55 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 12 |
| Spironolactone | Spironolactone | 53 | suppressed |
| Ibuprofen | Ibuprofen | 52 | 21 |
| Rybelsus | Semaglutide | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 46 | suppressed |
| Irbesartan | Irbesartan | 45 | suppressed |
| Linzess | Linaclotide | 45 | suppressed |
| Telmisartan | Telmisartan | 45 | suppressed |
| Azithromycin | Azithromycin | 43 | 38 |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | suppressed |
| Pregabalin | Pregabalin | 43 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 40 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 39 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | 12 |
| Meclizine Hcl | Meclizine Hcl | 39 | 13 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Diazepam | Diazepam | 37 | suppressed |
| Levetiracetam | Levetiracetam | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Nystatin | Nystatin | 36 | 14 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Glipizide Er | Glipizide | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Kerendia | Finerenone | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 27 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 11 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Rivastigmine | Rivastigmine | 25 | suppressed |
| Temazepam | Temazepam | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Entresto | Sacubitril/Valsartan | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 18 | suppressed |
| Lidocaine | Lidocaine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Edarbi | Azilsartan Medoxomil | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $555.37 · 31 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, GVOKE HYPOPEN, IBSRELA, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, Wegovy, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error